Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Lisata Therapeutics, Inc. (NASDAQ:LSTA) has appointed Jeffrey Farrow to its Board of Directors as an independent Class III director, effective October 13, 2026. Farrow joins the Audit Committee and fills a newly created seat, expanding the total board size from seven to eight members. He currently serves as Chief Financial Officer and Chief Strategy Officer at Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) and brings more than 15 years of financial leadership in public biopharmaceutical companies.
The appointment adds corporate finance experience to the clinical-stage biotechnology company. Farrow has previously held chief financial officer positions at several biopharmaceutical firms through commercialization and strategic acquisitions, including Global Blood Therapeutics, ZS Pharma, and Hyperion Therapeutics. Lisata management cited his experience bringing drugs from clinical development to commercial launch as a core asset for the board.
Moving forward, stakeholders will watch Lisata's execution across its main development programs. The company is currently advancing Phase 2b clinical studies for lead product candidate MAR001 in severe hypertriglyceridemia, as well as MAR002 for acromegaly. Lisata is also continuing development of certepetide, an investigational cyclic peptide designed to help solid tumor treatments penetrate cancerous tissue.
Key points
- Jeffrey Farrow was appointed as an independent Class III director and Audit Committee member at Lisata Therapeutics, effective October 13, 2026.
- The appointment expands Lisata's Board of Directors from seven to eight members.
- Farrow currently serves as CFO and Chief Strategy Officer at Tarsus Pharmaceuticals, bringing over 15 years of public biopharma leadership experience.
- Lisata is progressing Phase 2b clinical programs for its candidates MAR001 in severe hypertriglyceridemia and MAR002 in acromegaly.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Who was appointed to the Board of Directors at Lisata Therapeutics?
Jeffrey Farrow was appointed as an independent Class III director and Audit Committee member, expanding Lisata's board to eight members.
What are Lisata Therapeutics' key clinical programs?
Lisata is advancing MAR001 in Phase 2b trials for severe hypertriglyceridemia, MAR002 for acromegaly, and certepetide for solid tumor drug uptake.
What executive position does Jeff Farrow currently hold?
Jeff Farrow is the Chief Financial Officer and Chief Strategy Officer at Tarsus Pharmaceuticals, Inc.